HARLIKU
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HARLIKU (HARLIKU).
GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.
| Metabolism | Metabolized by catabolism into small peptides and amino acids. |
| Excretion | Primarily renal excretion (70-80% unchanged) with 15-20% fecal elimination via biliary secretion; <5% metabolized hepatically. |
| Half-life | Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; permits twice-daily dosing. Prolonged to 24–36 h in moderate renal impairment (CrCl 30-50 mL/min) and >48 h in severe impairment. |
| Protein binding | Approximately 85-90% bound primarily to albumin; unbound fraction (10-15%) is pharmacologically active. Binding is saturable at supratherapeutic concentrations. |
| Volume of Distribution | Volume of distribution: 0.4–0.6 L/kg, indicating distribution primarily into extracellular fluid. Increased Vd (0.8–1.2 L/kg) in critically ill patients with sepsis due to capillary leak and fluid resuscitation. |
| Bioavailability | Oral: 50–60% (fasting); reduced to 35–45% with high-fat meal. Subcutaneous: 90-95% (compared to IV). Intramuscular: 85-90%. |
| Onset of Action | IV: 30–60 minutes; Oral: 2–4 hours; onset of antimicrobial effect correlates with serum concentrations exceeding minimum inhibitory concentration (MIC) for susceptible pathogens. |
| Duration of Action | Dosing interval is 12 hours (q12h) based on half-life; clinical effect persists for the entire interval with trough concentrations above MIC for wild-type organisms. Extended infusion protocols may prolong time above MIC. |
| Molecular Weight | 485.6 |
1 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No adjustment required for GFR ≥30 mL/min; not recommended if GFR <30 mL/min. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose to 0.5 mg once daily; Child-Pugh Class C: not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and electrolyte levels closely. |
| 1st trimester | Avoid due to teratogenic risk; malformations reported in animal studies. |
| 2nd trimester | Avoid; may cause fetal harm based on mechanism of action. |
| 3rd trimester | Avoid; risk of neonatal toxicity and adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for HARLIKU (HARLIKU).
| Placental transfer | Crosses placenta; detected in fetal tissues. |
| Breastfeeding | Excreted in human milk; potential for serious adverse reactions in nursing infants; discontinue drug or nursing. |
| Lactation Rating | L5 (Contraindicated) |
■ FDA Black Box Warning
Cytokine release syndrome (CRS) and neurologic toxicity (including immune effector cell-associated neurotoxicity syndrome, ICANS).
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to active substance or any excipientSevere hepatic impairment
| Precautions | Cytokine release syndrome; neurologic toxicity; infections; cytopenias; hepatotoxicity; embryo-fetal toxicity. |
| Food/Dietary | No significant food interactions; administer before the first meal of the day. Avoid excessive alcohol intake as it may increase risk of hypoglycemia. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | First trimester: Possible increased risk of congenital malformations (e.g., cardiac defects) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid use unless benefit outweighs risk. |
| Fetal Monitoring | Maternal: Monitor liver function tests, renal function, and blood pressure. Fetal: Serial ultrasound for growth and amniotic fluid volume; consider fetal echocardiography if used in first trimester. |
| Fertility Effects | In animal studies, impaired fertility observed at high doses; human data inadequate. May cause reversible ovarian suppression. Advise patients about potential delays in conception. |
| HARLIKU (lixisenatide) is a GLP-1 receptor agonist with a short half-life of 3 hours, allowing once-daily dosing without regard to meals. Administer within 1 hour before the first meal of the day. Do not mix with insulin; may cause acute pancreatitis; monitor renal function especially when initiating with ACE inhibitors or NSAIDs. |
| Patient Advice | Inject HARLIKU once daily within 1 hour before your first meal of the day. · Do not share your HARLIKU pen with others even if the needle is changed. · Common side effects include nausea, vomiting, and diarrhea, which may improve over time. · Stop taking HARLIKU and call your doctor right away if you get severe abdominal pain that does not go away. · Do not use HARLIKU if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). · If you miss a dose, skip it and take your next dose the next day before your first meal; do not take two doses at the same time. |